Professor Jamie Vandenberg completed his Medical training at the University of Sydney, his PhD in the Department of Biochemistry at the University of Cambridge and undertook post-doctoral training at the Universities of Oxford and Cambridge. In 2002 he moved to the Victor Chang Cardiac Research Institute in Sydney where he is head of the Mark Cowley Lidwill Research Program in Cardiac Electrophysiology and co-Deputy Director. Jamie Vandenberg is a cardiac electrophysiologist whose work focuses on the molecular basis of inherited and drug-induced arrhythmia syndromes.

Professor Maciej Tomaszewski is a clinician-scientist interested in cardiovascular and renal disease, in particular – hypertension. After completion of his MD, he was awarded a junior International Society of Hypertension clinical research fellowship (at the University of Glasgow) and subsequently career development awards from the Wellcome Trust, the Scottish Chief Scientist Office, and USA National Institute of Health (NIH). In 2006 he was appointed to a competitive New Blood Lectureship at the University of Leicester. Between 2009 and 2015 he was a senior clinical lecturer at the Department of Cardiovascular Sciences in Leicester. In 2015 he was awarded Chair of Cardiovascular Medicine in the Division of Cardiovascular Sciences, University of Manchester, and an honorary consultant physician position at the Manchester University NHS Foundation Trust. He is a co-lead for the Integrative Cardiovascular Medicine Theme of NIHR Manchester Biomedical Research Centre and Deputy Director of British Heart Foundation Centre of Research Excellence in Manchester. Professor Tomaszewski is known for his international leadership in hypertension. He is a member of the Scientific Council of the International Society of Hypertension (ISH). Between 2016 and 2018 he served as ISH Secretary and between 2020 and 2022 he was President of the Society and chairman of both its Scientific Council and the Executive Committee. He has been on Editorial Boards of leading hypertension journals including Hypertension, Journal of Hypertension, Journal of Human Hypertension and Blood Pressure. He is Associate Editor for Cardiovascular Research and International Consulting Editor for Hypertension Research and chairs the International Society of Hypertension-European Society of Hypertension Journal of Hypertension Committee. He is also a Fellow of the American Heart Association, International Society of Hypertension, and Royal College of Physicians (London). Professor Tomaszewski played an active role on the Programme Committees of several international meetings organised by the International and European Society of Hypertension and served on Guidelines Taskforces/Committees dedicated to the management of hypertension. He received several academic accolades including awards from the European Society of Hypertension, the International Society of Hypertension, the American Heart Association, and the European Atherosclerosis Society. His basic research focuses on genetic mechanisms of cardiovascular and renal diseases. He established one the largest collections of human kidney tissue characterised at genome-, transcriptome-, and epigenome-wide levels to facilitate translation of findings from genome-wide association studies into specific genes, molecules, and pathways underpinning the genetic associations with blood pressure, chronic kidney disease, and other complex polygenic traits. The insights delivered from Human Kidney Tissue Resource-based projects have been published in top journals including Nature Genetics, European Heart Journal, Nature Communications, Kidney International, Journal of the American Society of Nephrology, etc. Professor Tomaszewski’s clinical research focuses on the management of difficult-to-treat hypertension. He led the implementation of high-performance liquid chromatography-based urine analysis as a direct, non-invasive, and objective screening tool for non-adherence to antihypertensive treatment. He has been driving the integration of the biochemical screening for non-adherence to blood pressure lowering therapy into the routine diagnostic strategy for resistant hypertension locally, nationally, and internationally through his contributions to Global Hypertension Practice Guidelines and the European Society of Hypertension Working Group on Cardiovascular Pharmacotherapy and Adherence (of which he was a founding member). He is a chief investigator and chair of the Trial Management Committee of the British Heart Foundation-funded multi-centre BiOmarkers in Urine, anTihypeRtensive trEAtment and blood pressure Control in Hypertensive patients (OUTREACH) study.

Mauro Giacca, MD PhD, is Past-President of the ISHR-ES. He is Head of the School of Cardiovascular and Metabolic Medicine&Sciences at King’s College London, UK and Director of the Centre of Excellence for Advanced Therapies for Cardiac Repair and Regeneration (RECREATE) of the Medical Research Council, UK. Until 2019, he has served as Director-General of ICGEB, a United Nations organization. Since 2005, he is Full Professor of Molecular Biology at the University of Trieste, Italy. He is the founder of Forcefield Therapeutics and Heqet Therapeutics, two startups that develop advanced therapies for myocardial infarction and heart failure. Prof Giacca is an elected Fellow of the Academy of Medical Sciences, UK and of ISHR.